• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Reinfection rates among patients previously testing positive for COVID-19

byBrian DoughertyandAlex Chan
March 25, 2021
in Infectious Disease, Public Health, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

#VisualAbstract: Molnupiravir improves outcomes in non-hospitalized COVID-19 patients

Risk of myocarditis or pericarditis after COVID-19 mRNA vaccination is highest among younger males

Vaccination boosted immunity acquired from previous SARS-CoV-2 infection

1. Among a large U.S. cohort, previous infection with SARS-CoV-2 appears to confer high levels of immunity against reinfection for at least 8 months.

Evidence Level Rating: 2 (Good)

As of early March 2021, SARS-CoV-2 has infected nearly 120 million individuals worldwide. The subsequent duration of immunity to reinfection is unknown; infection with common seasonal coronavirus does not tend to confer lasting immunity. Vaccination against SARS-CoV-2 is increasing, but due to shortages, nearly all countries have implemented prioritization schemes. Having a more robust understanding of immunity after confirmed infection has the potential to affect these schemes by delaying vaccination for those with likely immunity to allow access for the more vulnerable. This large cohort study included 612,611 tests from 386,336 individuals (mean [SD] age = 51.4 [22.4] years, 54.5% female) across one healthcare system in both Ohio and Florida, with a 9.9% overall positivity rate. Initial infection status was based on PCR testing performed prior to 30 August 2020. 150,325 patients had tests performed prior to this date, with 8,845 testing positive. After at least 90 days, 1,278 of these previously positive patients were retested, with 62 reviewed for reinfection. 31 of these reinfected patients were symptomatic, and 18 were hospitalized within 30 days of the positive test. The average time to reinfection was 138.9±46.3 days. Among those who initially tested negative, 27.9% (39,487/141,480) were retested, with 5,449 testing positive. Overall, the protection of prior infection against reinfection was determined to be 81.8% (95% CI 76.6% to 85.8%), while against symptomatic infection it was 84.5% (95% CI 77.9% to 89.1%). Protection against reinfection was lowest in months 4 to 5 and increased for up to 8 months after initial infection. There are numerous limitations of this study, such as including only tests from one healthcare system, the possibility of persistent viral shedding from the initial infection past 90 days, and unknown behavioral changes following initial infection affecting future exposures. However, it appears that previous SARS-CoV-2 infection confers high levels of protection against reinfection for at least 8 months, suggesting that patients previously infected may defer vaccination to allow for inoculation of more vulnerable individuals.

Click to read the study in Clinical Infectious Diseases

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: SARS-CoV-2
Previous Post

#VisualAbstract: Pegcetacoplan improved hemoglobin levels in eculizumab-treated paroxysmal nocturnal hemoglobinuria patients

Next Post

#VisualAbstract CARDAMON case series: Thrombotic microangiopathy in newly diagnosed multiple myeloma patients receiving carfilzomib, cyclophosphamide, and dexamethasone can be preventatively managed

RelatedReports

#VisualAbstract: Molnupiravir improves outcomes in non-hospitalized COVID-19 patients
StudyGraphics

#VisualAbstract: Molnupiravir improves outcomes in non-hospitalized COVID-19 patients

June 30, 2022
Atrial fibrillation-specific management increases days alive and out of hospital
Cardiology

Risk of myocarditis or pericarditis after COVID-19 mRNA vaccination is highest among younger males

June 22, 2022
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

Vaccination boosted immunity acquired from previous SARS-CoV-2 infection

May 13, 2022
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

Single-dose Ad26.COV2.S vaccine provides moderate protection against Covid-19 related outcomes

May 13, 2022
Next Post
#VisualAbstract CARDAMON case series: Thrombotic microangiopathy in newly diagnosed multiple myeloma patients receiving carfilzomib, cyclophosphamide, and dexamethasone can be preventatively managed

#VisualAbstract CARDAMON case series: Thrombotic microangiopathy in newly diagnosed multiple myeloma patients receiving carfilzomib, cyclophosphamide, and dexamethasone can be preventatively managed

#VisualAbstract: Early discontinuation of endocrine therapy may increase risk of breast cancer recurrence in premenopausal women

#VisualAbstract: BRAF and MEK inhibitor combination therapy shows efficacy for advanced melanoma in Japanese patients

#VisualAbstract Brief pembrolizumab monotherapy followed by doxorubicin, vinblastine, and dacarbazine was both effective and safe in untreated early unfavourable and advanced stage classical Hodgkin lymphoma

#VisualAbstract Brief pembrolizumab monotherapy followed by doxorubicin, vinblastine, and dacarbazine was both effective and safe in untreated early unfavourable and advanced stage classical Hodgkin lymphoma

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.